Table 3.
Logistic regression analysis of the TGF-β2 and TGF-βR2 polymorphism in ESRD patients and controls after adjusting for age and sex
| SNPs | Genotype / allele | Normal | ESRD | Models | OR (95% CI) | P |
|---|---|---|---|---|---|---|
| n (%) | n (%) | |||||
| rs7550232 | A/A | 256 (84.8) | 226 (87.6) | Codominant 1 | 0.75 (0.46–1.24) | 0.263 |
| TGF-β2 | A/C | 45 (14.9) | 30 (11.6) | Codominant 2 | 2.29 (0.21–25.40) | 0.50 |
| C/C | 1 (0.3) | 2 (0.8) | Dominant | 0.79 (0.48–1.28) | 0.33 | |
| Recessive | 2.37 (0.21–26.34) | 0.47 | ||||
| Log-additive | 0.84 (0.53–1.32) | 0.44 | ||||
| rs2228048 | C/C | 169 (54.2) | 131 (51.6) | Codominant 1 | 1.11 (0.78–1.58) | 0.56 |
| TGF-βR2 | C/T | 117 (37.5) | 101 (39.8) | Codominant 2 | 1.09 (0.59–2.01) | 0.78 |
| T/T | 26 (8.3) | 22 (8.7) | Dominant | 1.11 (0.79–1.54) | 0.55 | |
| Recessive | 1.04 (0.58–1.89) | 0.89 | ||||
| Log-additive | 1.07 (0.83–1.38) | 0.60 | ||||
| rs764522 | C/C | 255 (81.7) | 189 (73.3) | Codominant 1 | 1.65 (1.10–2.47) | 0.016 |
| TGF-βR2 | C/G | 54 (17.3) | 66 (25.6) | Codominant 2 | 1.34 (0.27–6.75) | 0.72 |
| G/G | 3 (1.0) | 3 (1.2) | Dominant | 1.63 (1.09–2.43) | 0.016 | |
| Recessive | 1.21 (0.24–6.07) | 0.82 | ||||
| Log-additive | 1.54 (1.06–2.24) | 0.022 | ||||
| rs3087465 | G/G | 224 (72.3) | 161 (62.4) | Codominant 1 | 1.63 (1.13–2.35) | 0.009 |
| TGF-βR2 | G/A | 76 (24.5) | 89 (34.5) | Codominant 2 | 1.11 (0.43–2.88) | 0.83 |
| A/A | 10 (3.2) | 8 (3.1) | Dominant | 1.57 (1.10–2.24) | 0.013 | |
| Recessive | 0.96 (0.37–2.46) | 0.93 | ||||
| Log-additive | 1.39 (1.03–1.90) | 0.033 |
CI, confidence interval; ESRD, end-stage renal disease; OR, odds ratio; SNP, single-nucleotide polymorphism; TGF-β, transforming growth factor-beta; TGF-βR2, transforming growth factor-β receptor 2.